Ngā hua rapu - Jeffrey Botbyl
- E whakaatu ana i te 1 - 4 hua o te 4
-
1
Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder mā Yuri Maricich, Warren K. Bickel, Lisa A. Marsch, Kirstin M. Gatchalian, Jeffrey Botbyl, Hilary F. Luderer
I whakaputaina 2020Artigo -
2
-
3
Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas mā Phyllis A. Gimotty, David E. Elder, Douglas L. Fraker, Jeffrey Botbyl, Kimberly F. Sellers, Rosalie Elenitsas, Michael E. Ming, Lynn M. Schuchter, Francis R. Spitz, Brian J. Czerniecki, DuPont Guerry
I whakaputaina 2007Artigo -
4
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial mā Brian G. Rash, Kevin Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain‐Moss, Zarin Zainul, Brittany Varnado, Kevin Peterson, Michael Brown, Thiago Peixoto Leal, Steven Kopcho, Raul Carballosa, Paayal Patel, Mark Brody, Brad Herskowitz, Ana Fuquay, Savannah Rodriguez, Alan F. Jacobson, Ramón Fernández de León, Michael A. Pfeffer, Julie Schwartzbard, Jeffrey Botbyl, Anthony A. Oliva, Joshua M. Hare
I whakaputaina 2025Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Pathology
Biology
Cancer
Cancer research
Clinical trial
Randomized controlled trial
AJCC staging system
Adjunct
Adverse effect
Alternative medicine
Atrophy
Biochemistry
Buprenorphine
Cancer registry
Cancer staging
Cell biology
Clinical endpoint
Cognitive decline
Dementia
Dermatology
Disease
Environmental health
Epidemiology
Gastroenterology
Gene
Gene expression
Immunohistochemistry
In situ hybridization